The historical rank and industry rank for MoonLake Immunotherapeutics's PB Ratio or its related term are showing as below:
MLTX'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 5.77
Current: 5.65
During the past 5 years, MoonLake Immunotherapeutics's highest PB Ratio was 5.77. The lowest was 0.00. And the median was 0.00.
MLTX's PB Ratio is ranked worse than 74.51% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs MLTX: 5.65
During the past 12 months, MoonLake Immunotherapeutics's average Book Value Per Share Growth Rate was -39.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 50.40% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of MoonLake Immunotherapeutics was 50.40% per year. The lowest was 50.40% per year. And the median was 50.40% per year.
Back to Basics: PB Ratio
MoonLake Immunotherapeutics (NAS:MLTX) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
MoonLake Immunotherapeutics PB Ratio Related Terms
MoonLake Immunotherapeutics PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MoonLake Immunotherapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MoonLake Immunotherapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where MoonLake Immunotherapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
MoonLake Immunotherapeutics (MLTX) has a PB Ratio of 5.65 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on MoonLake Immunotherapeutics and its competitors. According to the industry distribution chart, MoonLake Immunotherapeutics ranks #918 out of 1232 companies in the Biotechnology industry, placing it in the top 74.5%.
Is MoonLake Immunotherapeutics' PB Ratio too high?
MoonLake Immunotherapeutics' current PB Ratio is 5.65. The Biotechnology industry median PB Ratio is 2.80. MoonLake Immunotherapeutics' value of 5.65 is 101.8% above this industry median. Based on the distribution chart, MoonLake Immunotherapeutics ranks #918 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MoonLake Immunotherapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' PB Ratio compare to AVBP and BCAX?
According to the Biotechnology industry distribution chart, MoonLake Immunotherapeutics ranks #918 out of 1232 companies for PB Ratio. This places MoonLake Immunotherapeutics in the lower half of its industry. The industry median PB Ratio is 2.80. MoonLake Immunotherapeutics' value of 5.65 is 101.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MoonLake Immunotherapeutics's current PB Ratio of 5.65 is 101.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on MoonLake Immunotherapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MoonLake Immunotherapeutics's current PB Ratio is 5.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MLTX) has a current PB Ratio of 5.65. The current PB Ratio is 5.65 and 101.8% above the Biotechnology industry median of 2.80. MoonLake Immunotherapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MLTX), the current PB Ratio is 5.65 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
30GF Score
Get the complete analysis for MLTX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLTX has been successfully added to your 
